AEterna Zentaris Inc. (AEZS) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.05, Morningstar.com reports. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. AEterna Zentaris had a negative net margin of 2,732.69% and a negative return on equity of 425.52%. AEterna Zentaris’s revenue for the quarter was up 153.1% compared to the same quarter last year.
Shares of AEterna Zentaris (NASDAQ:AEZS) opened at 1.73 on Friday. The firm’s 50-day moving average price is $1.53 and its 200-day moving average price is $2.09. AEterna Zentaris has a 52-week low of $0.78 and a 52-week high of $5.59. The stock’s market cap is $24.80 million.
Several equities research analysts recently issued reports on AEZS shares. HC Wainwright dropped their price objective on AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Maxim Group set a $2.00 price objective on AEterna Zentaris and gave the company a “buy” rating in a research note on Monday, May 1st. Finally, Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th.
WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/aeterna-zentaris-inc-aezs-posts-earnings-results-beats-expectations-by-0-20-eps/1470987.html.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.